Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

miRNA as activity markers in Parvo B19 associated heart disease.

Kühl U, Rohde M, Lassner D, Gross UM, Escher F, Schultheiss HP.

Herz. 2012 Sep;37(6):637-43.

PMID:
22872003
2.

Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy.

Escher F, Modrow S, Sabi T, Kühl U, Lassner D, Schultheiss HP, Noutsias M.

Med Sci Monit. 2008 Dec;14(12):CR589-97.

PMID:
19043365
3.

A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression.

Kuhl U, Lassner D, Dorner A, Rohde M, Escher F, Seeberg B, Hertel E, Tschope C, Skurk C, Gross UM, Schultheiss HP, Poller W.

Basic Res Cardiol. 2013 Sep;108(5):372. doi: 10.1007/s00395-013-0372-y. Epub 2013 Aug 11. Erratum in: Basic Res Cardiol. 2014 Jan;109(1):394.

PMID:
23934091
4.

Adaptive immune responses against parvovirus B19 in patients with myocardial disease.

Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, Modrow S.

J Clin Virol. 2009 Jan;44(1):27-32. doi: 10.1016/j.jcv.2008.09.007. Epub 2008 Nov 5.

PMID:
18980860
5.

Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy.

Greulich S, Kindermann I, Schumm J, Perne A, Birkmeier S, Grün S, Ong P, Schäufele T, Klingel K, Schneider S, Kandolf R, Böhm M, Sechtem U, Mahrholdt H.

Clin Res Cardiol. 2016 Jan;105(1):37-52. doi: 10.1007/s00392-015-0884-6. Epub 2015 Jul 2.

PMID:
26133158
6.

Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction.

Klein RM, Jiang H, Niederacher D, Adams O, Du M, Horlitz M, Schley P, Marx R, Lankisch MR, Brehm MU, Strauer BE, Gabbert HE, Scheffold T, Gülker H.

Z Kardiol. 2004 Apr;93(4):300-9.

PMID:
15085375
7.

Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis.

Kuethe F, Lindner J, Matschke K, Wenzel JJ, Norja P, Ploetze K, Schaal S, Kamvissi V, Bornstein SR, Schwanebeck U, Modrow S.

Clin Infect Dis. 2009 Dec 1;49(11):1660-6. doi: 10.1086/648074.

PMID:
19863443
8.

Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury.

Lotze U, Egerer R, Glück B, Zell R, Sigusch H, Erhardt C, Heim A, Kandolf R, Bock T, Wutzler P, Figulla HR.

J Med Virol. 2010 Aug;82(8):1449-57. doi: 10.1002/jmv.21821.

PMID:
20572082
9.

Genotype-specific effects on left ventricular function in parvovirus B19-positive patients with dilated cardiomyopathy.

Ruppert V, Meyer T, Balbach A, Richter A, Müller HH, Maisch B, Pankuweit S; German Heart Failure Network.

J Med Virol. 2011 Oct;83(10):1818-25. doi: 10.1002/jmv.22187.

PMID:
21837800
10.

Parvovirus B19 infection mimicking acute myocardial infarction.

Kühl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, Krautwurm L, Poller W, Schultheiss HP, Kandolf R.

Circulation. 2003 Aug 26;108(8):945-50. Epub 2003 Aug 18.

11.

Human parvovirus B19-associated myocarditis.

Bock CT, Klingel K, Kandolf R.

N Engl J Med. 2010 Apr 1;362(13):1248-9. doi: 10.1056/NEJMc0911362. No abstract available.

12.

Hepatic dysfunction due to parvovirus B19 infection.

Díaz F, Collazos J.

J Infect Chemother. 2000 Mar;6(1):63-4.

PMID:
11810534
13.

Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles.

Bachelier K, Biehl S, Schwarz V, Kindermann I, Kandolf R, Sauter M, Ukena C, Yilmaz A, Sliwa K, Bock CT, Klingel K, Böhm M.

PLoS One. 2017 May 22;12(5):e0176311. doi: 10.1371/journal.pone.0176311. eCollection 2017.

14.

Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens.

Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B.

Hum Pathol. 2003 May;34(5):497-503.

PMID:
12792925
15.

Prevalence and association of human parvovirus B19V with hepatitis B and C viruses in Nigeria.

Opaleye OO, Fagbami AH, Lalremruata A, Kun JF.

J Med Virol. 2011 Apr;83(4):710-6. doi: 10.1002/jmv.22008.

PMID:
21328387
16.

Identification of past and recent parvovirus B19 infection in immunocompetent individuals by quantitative PCR and enzyme immunoassays: a dual-laboratory study.

Maple PA, Hedman L, Dhanilall P, Kantola K, Nurmi V, Söderlund-Venermo M, Brown KE, Hedman K.

J Clin Microbiol. 2014 Mar;52(3):947-56. doi: 10.1128/JCM.02613-13. Epub 2014 Jan 8.

17.

Acute hepatitis as a manifestation of parvovirus B19 infection.

Hatakka A, Klein J, He R, Piper J, Tam E, Walkty A.

J Clin Microbiol. 2011 Sep;49(9):3422-4. doi: 10.1128/JCM.00575-11. Epub 2011 Jul 6.

18.

[Endomyocardial biopsy-guided diagnosis and treatment of inflammatory cardiomyopathies].

Pankuweit S, Lamparter S, Funck R, Maisch B.

Dtsch Med Wochenschr. 2004 Oct 8;129(41):2169-72. German.

PMID:
15457396
19.

Serological and Molecular Biological Studies of Parvovirus B19, Coxsackie B Viruses, and Adenoviruses as Potential Cardiotropic Viruses in Bulgaria.

Ivanova SK, Angelova SG, Stoyanova AP, Georgieva IL, Nikolaeva-Glomb LK, Mihneva ZG, Korsun NS.

Folia Med (Plovdiv). 2016 Dec 1;58(4):250-256. doi: 10.1515/folmed-2016-0036.

PMID:
28068282
20.

Successful immunotherapy in life-threatening parvovirus B19 infection in a child.

Butin M, Mekki Y, Phan A, Billaud G, Di Filippo S, Javouhey E, Cochat P, Belot A.

Pediatr Infect Dis J. 2013 Jul;32(7):789-92. doi: 10.1097/INF.0b013e31828df4d1.

PMID:
23429554

Supplemental Content

Support Center